학술논문
NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.
Document Type
Academic Journal
Author
Flaig TW; Spiess PE; Agarwal N; Bangs R; Boorjian SA; Buyyounouski MK; Downs TM; Efstathiou JA; Friedlander T; Greenberg RE; Guru KA; Hahn N; Herr HW; Hoimes C; Inman BA; Jimbo M; Kader AK; Lele SM; Meeks JJ; Michalski J; Montgomery JS; Pagliaro LC; Pal SK; Patterson A; Petrylak DP; Plimack ER; Pohar KS; Porter MP; Preston MA; Sexton WJ; Siefker-Radtke AO; Tward J; Wile G; Johnson-Chilla A; Dwyer MA; Gurski LA
Source
Publisher: Harborside Press Country of Publication: United States NLM ID: 101162515 Publication Model: Print Cited Medium: Internet ISSN: 1540-1413 (Electronic) Linking ISSN: 15401405 NLM ISO Abbreviation: J Natl Compr Canc Netw Subsets: MEDLINE
Subject
Language
English
Abstract
The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 version of the guidelines, including implications of the 8th edition of the AJCC Cancer Staging Manual on treatment of muscle-invasive bladder cancer and incorporating newly approved immune checkpoint inhibitor therapies into treatment options for patients with locally advanced or metastatic disease.
(Copyright © 2018 by the National Comprehensive Cancer Network.)
(Copyright © 2018 by the National Comprehensive Cancer Network.)